HZ
Huda Y Zoghbi
Director

Huda Y Zoghbi insider trades: Regeneron Pharmaceuticals (REGN) stock sales

Director, Regeneron Pharmaceuticals Last trade Nov 3, 2026 20 Form 4 filings
$9.1M
Sold, last 12 months
3 sales
$0
Bought, last 12 months
0 buys
10
Open-market trades
since 2020
1
Company
last trade 2026

Trades on the price chart

Daily close, with an arrow on each day they bought or sold

Companies

Where Huda reports to the SEC

Open-market buys and sales

10 trades reported on SEC Form 4, newest first

DateStockTypeValue
Nov 3, 2026REGN↓ Sell$7.2M
Aug 10, 2026REGN↓ Sell$640K
Feb 19, 2026REGN↓ Sell$1.3M
Jan 2, 2024REGN↓ Sell$1.0M
Oct 13, 2023REGN↓ Sell$850K
Mar 16, 2022REGN↓ Sell$1.4M
Sep 14, 2021REGN↓ Sell$650K
Jul 7, 2020REGN↓ Sell$1.1M
Jun 11, 2020REGN↓ Sell$2.1M
May 7, 2020REGN↓ Sell$2.9M

Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.

Other REGN insiders

Open-market trades in the last 12 months

About Huda Y Zoghbi's insider trades

Huda Y Zoghbi is a director at Regeneron Pharmaceuticals (REGN). Since May 7, 2020, Huda has reported no open-market purchases and 10 sales worth $19.1M on SEC Form 4. In the last 12 months: 3 sales ($9.1M).

Their filings also include grants and awards (11 filings), option exercises (10 filings). These aren't open-market trades and aren't counted above.

How to read insider trades

Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every REGN insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.